|
Ixico PLC on Thursday said it has been awarded a contract worth £2.1 million with a ‘leading’ global pharmaceutical company for a phase two Huntington's disease trial.
The neuroscience data analytics company has been selected to support a drug development program for Huntington's disease, a rare, neurological condition leading to irreversible decline and death.
The company is to assist with the design and implementation of clinical research by providing services such as its Trail Tracker platform, which enables imaging centres to upload anonymised MRI scans to Ixico.
‘We are delighted to continue our partnership with one of the world's leading pharmaceutical companies working in the field of neurodegenerative diseases. We have been working closely with this customer in Huntington's and the broader research community for many years and continue to play a leading role in leveraging our Neuroimaging expertise and advanced analytics capabilities,’ said Chief Executive Officer Giulio Cerroni.
The trial, aimed at assessing the safety and efficacy of the drug, will finish at the end of 2024 and will focus on 300 patients with early manifest and prodromal Huntington's disease, the group said.
Shares in Ixico were up 7.7% at 32.85 pence in London on Thursday morning.
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
